Company Overview and News

 
Vedanta Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VEDL

 
Essar Steel: Arcelor withdraws letter listing Vedanta’s lapses

2018-09-17 livemint
Mumbai: ArcelorMittal India Pvt. Ltd has withdrawn its letter to the Essar Steel resolution professional (RP) wherein it had hinted that Vedanta may not be eligible to bid for the debt-laden company, given its patchy environmental and human rights record.
ESL VTBR 533264 36GK VEDL

 
Essar Steel auction: Numetal questions ArcelorMittal’s eligibility, writes to creditors, RP

2018-09-17 livemint
New Delhi: In a letter addressed to the resolution professional (RP) and the committee of creditors (CoC) conducting the auction of Essar Steel to recover over ₹49,000 crore of unpaid loans to banks, VTB Capital-backed Numetal on Monday questioned the eligibility of ArcelorMittal . This comes at a time when the matter is to be heard by the Supreme Court on Tuesday.
AMSYF MTCN 513142 MT 500228 BALASORE 513216 MT VEDL JSWSTEEL UTTAMSTL

 
ArcelorMittal backtracks after accusing Vedanta of environmental lapses

2018-09-17 moneycontrol
A day after ArcelorMittal wrote to the Essar Steel resolution professional accusing Vedanta Ltd of environmental and human rights violations, the Lakshmi Mittal-led company now claims that the mail was shared "inadvertently".
513216 VEDL UTTAMSTL

 
Essar Steel bid: ArcelorMittal targets Vedanta for environment, human rights violations

2018-09-17 moneycontrol
After targeting Russia's VTB Group-backed Numetal, ArcelorMittal has now targetted Vedanta Ltd - the third bidder in the race to acquire debt-laden Essar Steel, alleging environmental law and human rights violations by the Anil Agarwal firm.
ESL 533264 VEDL

1
VEDL / Vedanta Limited FORM 6-K (Current Report of Foreign Issuer)

2018-09-17 sec.gov - 1
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
VEDL

 
Vedanta Limited - Press Release

2018-09-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VEDL

 
Government approves fiscal incentives for projects to improve oil recovery

2018-09-12 moneycontrol
The government Wednesday approved fiscal incentives to attract investments and technology in raising oil and gas production from aging fields, which will unlock an estimated Rs 50 lakh crore of hydrocarbons in the next 20 years, Oil Minister Dharmendra Pradhan said.
VEDL

1
Essar Steel auction: SC to hear Arcelor’s plea against NCLAT tomorrow

2018-09-11 livemint - 1
New Delhi:The Supreme Court on Tuesday agreed to hear a plea of Arcelor Mittal tomorrow seeking extension of time for the payment of Rs 7,000 crore as ordered by the NCLAT last week for its bid to become eligible for Essar Steel.
500228 513216 VEDL JSWSTEEL UTTAMSTL

 
Income Tax Department sells more shares of Cairn Energy to recover retro tax

2018-09-11 moneycontrol
The Income Tax Department has sold more of Cairn Energy Plc's shares in mining major Vedanta Ltd to recover a part of the Rs 10,247 crore retrospective tax demand, the British firm said Tuesday.
CNE CRNZF VEDL CRNCY

 
ArcelorMittal sweetens Essar bid to Rs 42K-cr

2018-09-11 freepressjournal.in
Mumbai : Steel giant ArcelorMittal on Monday offered Rs 42,000 crore to acquire Essar Steel, upstaging a Rs 37,000 crore bid by Russia’s VTB Group-backed Numetal, sources with direct knowledge of the development said.
500228 VEDL JSWSTEEL

1
14 'Safer' Dividend 10%+Yield WallStars Sizzle In September

2018-09-05 seekingalpha
WallStars show positive broker target price upsides. 14 of 78 10%+ Yield WallStars were "safer" for dividends showing positive one-year returns and free cash flow yields greater than dividend yields 8/31/18.
CPLP SXCP ANH NBRXF ORC CIM SUN SNMP TCRX KDP DX TCRD TCRZ OSB VEDL TSLF GMLP GPP VEDL

 
Vedanta gets bauxite from Odisha, hopes to get more

2018-09-05 moneycontrol
Encouraged by supply of bauxite from the state-owned Odisha Mining Corporation (OMC), The Vedanta Limited is optimistic about completion of its refinery expansion project.
VEDL

 
VEDL / Vedanta Limited FORM 6-K (Current Report of Foreign Issuer)

2018-09-04 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
VEDL

 
[Press] Ashurst Advises Vedanta on US$551 Million Oil and Gas Block Bids

2018-09-03 oilvoice
International law firm Ashurst is advising longstanding client Vedanta Resources plc on the successful bid by its subsidiary, Vedanta Limited, for 41 exploration blocks in sedimentary basins throughout India to pursuant to the Government of India's Open Acreage Licensing Policy (OALP).
VED VEDL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 92242Y100